Ascletis Files IND for Oral GLP-1 and Amylin Combo
The once-daily tablet pairs two small-molecule candidates targeting obesity, and its developer is seeking U.S. FDA clearance to begin human testing.
Updated on Nov. 12, 2026 in Weight Loss

Ascletis Pharma Inc. has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for ASC30_39 FDC, a once-daily oral fixed-dose combination tablet pairing GLP-1 receptor agonist ASC30 with amylin receptor agonist ASC39. The filing is described as the first co-formulation of an oral GLP-1 and an oral amylin to reach IND submission.
Why it matters
Obesity drug development is moving toward oral options that combine multiple hormonal pathways. If cleared, the combination would advance a pill-based approach that its developer says is designed for room-temperature stability and a small tablet size.
The company reports preclinical half-life of up to 12 hours in dogs and a 40-fold selectivity of ASC39 for hAMY1R over hCTR. Human efficacy and safety for the combination have not been reported, and the comparisons cited come from non-head-to-head studies.
The players
Ascletis Pharma Inc.
A Hong Kong-listed clinical-stage biopharmaceutical company developing oral small-molecule therapies for metabolic diseases, including obesity.
The details
Ascletis, a Hong Kong-listed drug developer, said ASC30 and ASC39 were discovered in-house using its artificial intelligence-assisted structure-based drug discovery platform. The fixed-dose tablet was built with the company's proprietary formulation technology and is intended to be taken once daily.
Timeline
November 11, 2026: Ascletis announced the IND submission for ASC30_39 FDC.
Third quarter of 2028: Expected topline data from the AURORA Phase III clinical program.
Health Landscape
The filing places an oral GLP-1 and oral amylin combination alongside late-stage oral GLP-1 candidates such as orforglipron, with the company claiming a lower vomiting rate in non-head-to-head studies. Whether a two-hormone pill can match injectable incretin efficacy remains the central open question for this class.
For people with obesity, an oral once-daily option could eventually offer an alternative to injections, though no approval or availability exists yet. Any eventual treatment would still require clinical trial results showing efficacy and safety before reaching patients.
The takeaway
Oral obesity drugs are advancing on multiple fronts, but a combination pill must still prove in humans that it works and is well tolerated. Readers should watch for the AURORA Phase III results expected in 2028 before drawing conclusions.
What happens next
Ascletis expects topline data from the AURORA Phase III clinical program in the third quarter of 2028.
Further reading
Explore more on Weight Loss treatments and the drugs now in development.



